Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

Two people can read the same figure differently here and both be reasonable.

Acetate content can be a substantial fraction of the mass in a short peptide. A vial labelled 5 mg may contain appreciably less than 5 mg of peptide, and the certificate frequently does not say.

Anyone who has looked at this more carefully, please correct the record.

Worth separating two things that post #14 runs together.

Distinguishing three things in the Analytical identity of BPC-157 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

Comparisons between suppliers in this family are more meaningful than usual precisely because the analysis is straightforward. A supplier that cannot produce a clean result on a simple peptide has told you something.

Narrowing post #31, because the general version has more than one answer.

What I would tell a new member reading about Analytical identity of BPC-157 for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.